

State of Iowa
1986

ACTS AND JOINT RESOLUTIONS

PASSED AT THE

1986 REGULAR SESSION

OF THE

Seventy-first General Assembly

OF THE

STATE OF IOWA



JO ANN BROWN
ACTING CODE EDITOR

PHYLLIS BARRY
DEPUTY CODE EDITOR

Published by the
STATE OF IOWA
Des Moines

- a. Consigned to a federally approved market.
- b. Consigned to a slaughter plant for immediate slaughter.
- c. Accompanied by an official health certificate showing a record of a negative brucellosis test, when required, accomplished within thirty days of importation.

Sec. 9. Section 164.21, unnumbered paragraphs 1 and 2, Code 1985, are amended to read as follows:

The department shall certify the claim of the owner for each animal slaughtered in accordance with this chapter. An infected herd may be completely depopulated and indemnity paid ~~on individual animals~~ when, in the opinion of the officials of the department and officials of the ~~animal research~~ veterinary service of the United States department of agriculture, the disease cannot be adequately controlled by routine testing.

Indemnity ~~can~~ shall only be paid if money is available in the brucellosis and tuberculosis eradication fund and if indemnity payment is also made by the United States department of agriculture. However, if the United States department of agriculture is unable to pay indemnity, the state may still pay indemnity for condemned animals if money is available.

Approved April 7, 1986

CHAPTER 1037

SCHEDULE I AND II CONTROLLED SUBSTANCES

S.F. 2041

AN ACT relating to schedule I and schedule II controlled substances regulated by the board of pharmacy examiners.

Be It Enacted by the General Assembly of the State of Iowa:

Section 1. Section 204.204, subsection 4, lettered paragraph u, Code Supplement 1985, is amended to read as follows:

u. Tetrahydrocannabinols, except as otherwise provided by rules of the board of pharmacy examiners for medicinal purposes. Synthetic equivalents of the substances contained in the plant, or in the resinous extractives of *Cannabis sp.*, and synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as the following: Δ 1 cis or trans tetrahydrocannabinol, and their optical isomers, excluding dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States food and drug administration. Δ 6 cis or trans tetrahydrocannabinol, and their optical isomers. Δ 3,4 cis or trans tetrahydrocannabinol, and their optical isomers. (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.)

Sec. 2. Section 204.204, Code Supplement 1985, is amended by adding the following new subsection:

NEW SUBSECTION. 9. OTHER MATERIALS. Any material, compound, mixture, or preparation which contains any quantity of the following substances:

- a. 3-Methylfentanyl (N-[3-Methyl-1-[2-Phenylethyl]-4-piperidyl]-N-phenylpropanamide), its optical and geometric isomers, salts, and salts of isomers.
- b. 3,4-Methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts, and salts of isomers.
- c. 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and salts of isomers.

d. 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP) its optical isomers, salts, and salts of isomers.

e. N-[1-(1-methyl-2-phenyl)ethyl-4-piperidyl]-N-phenylacetamide (acetyl-alpha-methylfentanyl), its optical isomers, salts, and salts of isomers.

f. N-[1-(1-methyl-2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanamide (alpha-methylthiofentanyl), its optical isomers, salts, and salts of isomers.

g. N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (denzylfentanyl), its optical isomers, salts, and salts of isomers.

h. N-[1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide (beta-hydroxyfentanyl), its optical isomers, salts, and salts of isomers.

i. N-[3-methyl-1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide (beta-hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers.

j. N-[3-methyl-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanamide (3-methylthiofentanyl), its optical and geometric isomers, salts, and salts of isomers.

k. N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts, and salts of isomers.

l. N-[1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanamide (thiofentanyl), its optical isomers, salts, and salts of isomers.

Sec. 3. Section 204.206, subsection 2, lettered paragraph a, unnumbered paragraph 1, Code Supplement 1985, is amended to read as follows:

a. Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrophan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following:

Sec. 4. Section 204.206, subsection 7, Code Supplement 1985, is amended by striking the subsection and inserting in lieu thereof the following:

7. HALLUCINOGENIC SUBSTANCES. Marijuana is deemed to be a schedule II substance when used for medicinal purposes pursuant to rules of the board of pharmacy examiners. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved drug product. [Some other names for Dronabinol (6aR Trans)-6a, 7, 8, 10a-Tetrahydro-6, 6, 9-Trimethyl-3 pentyl-6H-dibenzol [b,d] pyran-1-01 or (-) delta 9-(trans)-tetrahydrocannabinol.]

Sec. 5. Section 204.206, Code Supplement 1985, is amended by adding the following new subsection:

NEW SUBSECTION. 8. The board of pharmacy examiners, by rule, may except any compound, mixture, or preparation containing any stimulant listed in subsection 4 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant effect on the central nervous system, and if the admixtures are included in such combinations, quantity, proportion, or concentration as to vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.

Approved April 7, 1986